COR-L23/R

Study of drug resistance, analysis of sub-cellular localisation of drugs, drug transport

Human Caucasian lung large cell carcinoma

The cell line COR-L23/R is a multi-drug resistant (MDR) sub-line derived from the parent line COR-L23 (Sigma Catalogue number. 92031919) after treatment with doxorubicin (adriamycin). The P-glycoprotein negative cell line is cross resistant to daunorubicin, vincristine and rhodamine 123. Drug resistance is caused by enhanced drug efflux that can be inhibited by addition of buthionine sulphoximide (BSO), an inhibitor of glutathione synthesis. COR-L23/R contain reduced levels of glutathione and glutathione-S-transferase activity compared to the parent line. MDR seems to be connected with overexpression of multi-drug resistance-associated protein (MRP) which is discussed as a drug transporter.

RPMI 1640 + 2mM Glutamine + 0.2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS). Start without drug. Add drug after first passage and then add at all subsequent passages.

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.